Latest From David Wallace
Hikma Still Sees Value In Generic Advair Despite Teva’s US Approval
Hikma expects healthy prospects for its US Advair generic in 2022, despite rival Teva recently receiving FDA approval for its own version. Meanwhile, Hikma CEO Siggi Olafsson also outlined expectations for generic competition on icosapent amid ongoing API shortages.
Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
Multiple Molecules See UK Prices More Than Double In December
WaveData’s compilation of the fastest-rising UK generics prices in December showed several products across multiple presentations more than doubling their average trade prices to independent pharmacists.
Hikma Buys Teligent Assets To Expand Into Canada
Hikma has snapped up the Canadian sterile injectables assets of bankrupt Teligent in a $46m deal that marks Hikma’s first move into Canada.
Does Hikma’s Vascepa Litigation Dismissal Suggest Safety For Skinny Labels?
An induced-infringement attack on Hikma’s skinny-label generic version of Vascepa had been cited as evidence of the potential harm that would be caused by controversial rulings in separate litigation involving GSK and Teva. However, these fears may now appear overstated after the claim against Hikma was dismissed.
Emergent Expects Narcan Generics To Face Uphill Struggle
US rivals to Narcan will face obstacles as they attempt to compete in the public interest market, Emergent’s CEO told the virtual J.P. Morgan Healthcare Conference.